SOURCE: IO Circuit

November 03, 2011 07:30 ET

TapImmune Inc. Announces Collaborative Work With Aeras

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO CIRCUIT.

NEW YORK, NY--(Marketwire - Nov 3, 2011) - TapImmune Inc. (OTCBB: TPIV) announced earlier this week they have begun a collaborative research and development agreement with Aeras, a non-profit product development organization.

The collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras. In a report published by the World Health Organization ( "The persistent TB epidemic and expanding global population ensure that the total market for range of TB diagnostic products is likely to grow over the coming decade."

TapImmune, similar to ImmunoGen (NASDAQ: IMGN), ImmunoCellular Therapeutics (OTCBB: IMUC) and Dendreon Corp (NASDAQ: DNDN) engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO NewsWire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information